Published in final edited form as:

Org Lett. 2008 November 6; 10(21): 4783–4786. doi:10.1021/ol801849u.

Diastereoselective Synthesis of Cyclopenta-pyridazinones via Radical Cyclization:

Synthetic Studies Towards Halichlorine

Gary E. Keck and Stacey A. Heumann

Department of Chemistry, University of Utah, 315 South 1400 East RM 2020 Salt Lake City, Utah, 84112-0850

Abstract

The pyridazinone ring system serves as an excellent scaffold for the diastereoselective preparation of novel *cis*-fused cyclopenta-pyridazinones utilizing the directed 5-*exo* radical cyclization approach. This overall approach was successfully employed in the preparation of a functionalized aza-spirocycle.

Intramolecular radical additions offer a powerful means for constructing both carbo- and hetero-cyclic ring systems.¹ There are numerous examples employing alkenes and alkynes as radical acceptors for ring formation,² and over the last decade, interest in imine-like^{1d,3} acceptors for radical cyclization reactions has steadily grown. Specifically, among these examples, the formation of cyclic structures using exocyclic imine-like acceptors has ample precedent.^{1d,3e,4} However the formation of fused ring systems using cyclic hydrazone acceptors as part of both stereo-defining and directing templates has been virtually unexplored.

In our pursuit to develop general methods for the synthesis of structural motifs found in biologically relevant molecules, pyridazinones appeared to be promising candidates for the synthesis of synthetically useful fused bicycles (Scheme 1). The embedded hydrazone could function as a radical acceptor and the ring's inherent rigidity could provide for the diastereoselective installation of the fused cyclopentane via a facile 5-*exo* radical cyclization. In addition, it was our intent to explore this radical reaction's potential to provide a key intermediate for use in efforts directed at the synthesis of the natural product halichlorine.

The chiral pyridazinone was easily accessed in five steps starting with 4-pentenoic acid **1** (Scheme 2). Initial amide coupling with (1R,2R)-(-)-pseudoephedrine was followed by the Myers' diastereoselective alkylation protocol⁵ using 1-chloro-3-iodo-propane. The auxiliary was subsequently removed with *n*-BuLi providing chiral ketone **2**.⁶ The terminal olefin in ketone **2** was then cleaved to give γ -keto acid **3**. Initial attempts to transform this substrate into the corresponding oxazinone **4** under a variety of conditions were fruitless.⁷ However, we were delighted to find that treatment of carboxylic acid **3** with hydrazine hydrate produced pyridazinone **5** in high yield, and that the use of methyl hydrazine led to *N*-methyl pyridazinone

6.^{7,8} It is important to recognize that oxazinone **4**, pyridazinone **5** and *N*-methyl pyridazinone **6** represent essentially equivalent substrates for our purposes; both oxime ethers and hydrazones have been shown to perform well as radical acceptors.³

In preparation for the radical cyclization, the chlorides in compounds **5** and **6** were exchanged for iodides using Finkelstein conditions (Scheme 3). To our delight, both pyridazinones **5** and **6** provided cyclopenta-pyridazinones **7** and **8** in good yield upon exposure to HSnBu₃ and azo-bis-cyclohexylnitrile (ACN) in toluene at reflux. As expected, the *cis*-fused bicycles were the only detectable diastereomers formed in the reaction. Thus the initial pyridazinone scaffold provides the necessary rigidity for efficient transfer of stereochemical information during the 5-*exo* radical cyclization. This addition thus leads to the generation of a new stereogenic center bearing a masked amino group.

In light of these successful radical cyclizations, we decided to explore this new method in a strategy directed at the synthesis of the biologically relevant natural product halichlorine. Specifically, we hoped to exploit this powerful method as the initial stereochemistry-defining reaction in the generation of the aza-spirocyclic core of halichlorine.

Halichlorine **9**⁹ is an alkaloid that was isolated from the marine sponge *Halichondria okadai* Kadota in 1996 by Uemura and co-workers (Scheme 4).¹⁰ The 15-membered macrolide has been shown to significantly inhibit the expression of VCAM-1 (vascular cell adhesion molecule). VCAM-1 is involved in promoting and regulating leukocyte uptake into inflamed tissue. Inhibition of this process is relevant to a variety of disease states, including asthma, atherosclerosis, coronary artery diseases, and noncardiovascular inflammatory diseases.^{10,11}

Retrosynthetically, halichlorine **9** can be dissected through a hydrolysis of the C₁-C₂₁ lactone followed by a disconnection of the C₁₅-C₁₆ olefin giving rise to the halichlorine spiroquinolizidine core **10** as well as *Z*-vinyl chloride **11** (Scheme 4). The core **10** can then be simplified by extrusion of the C₁,C₂,C₂₂ segment **12** to unveil the aza-spirocyclic **13**. The spirocycle **13** was envisioned to arise through an S_N2 displacement using a N-N bond-cleaved derivative of cyclopenta-pyridazinone **14**. This intermediate could be constructed stereoselectively using the 5-*exo* radical cyclization approach from pyridazinone **15**.

To access the pyridazinone with the desired substitution in place, the alkylated pseudoephedrine analogue **16** was treated with the alkyl lithium reagent derived from alkyl iodide **17** (Scheme 5). The olefin in the resulting ketone **18** was oxidatively cleaved with NaIO₄ and catalytic KMnO₄ to give the carboxylic acid that was then condensed with methyl hydrazine to provide the 'N-methyl protected' pyridazinone **19**. This was then followed by a rather daring alkylation of compound **19** with methyl iodide which afforded compound **20** in 94% yield, and as a single diastereomer.¹² The chloride in compound **20** was exchanged for an iodide, and as expected, cyclopenta-pyridazinone **21** was formed upon exposure to HSnBu₃ and ACN in toluene at reflux, in 86% yield over the two step sequence.

Elaboration to a simplified aza-spirocyclic was next explored (Scheme 6). Initially the N-N bond cleavage was attempted using dissolving metal conditions. Interestingly, while cyclopenta-pyridazinone **21** was fully consumed, only 15% of *cis*-fused cyclopenta-lactam **22** was isolated; none of the desired uncyclized compound was observed. This unexpected result prompted us to use alternative conditions. After acylation of the amine nitrogen, the N-N bond was reductively cleaved using SmI₂ to give the ring-opened trifluoroacetamide **23**.¹³ The TBS group was then removed and the primary alcohol **24** was treated under Mitsunobu conditions, which afforded the target aza-spirocyclic **25** in 69% yield.

The initial stereocenter obtained through Myers' alkylation, coupled with the rigidity of the pyridazinone radical acceptor, ultimately provided access to 3 of the 4 stereocenters found in

halichlorine. We envisioned that the remote C₅ stereocenter of the aza-spirocyclic found in the natural product might be accessed using the catalytic asymmetric allylation (CAA) reaction.¹⁴ Towards this end, the C₅ silyl ether **20** was converted into aldehyde **26** by removal of the TBS group followed by Swern oxidation (Scheme 7). Aldehyde **26** was then treated under the CAA conditions using *R*-BINOL. This reaction gave alcohol **27** in an excellent 85% yield as only one detectable diastereomer. In addition, aldehyde **26** was converted to the C₅ epimeric alcohol **epi-27** using *S*-BINOL under otherwise identical conditions; this ultimately proved important for establishing the relative and absolute configurations in this series.

The pyridazinone **27** was then treated under the radical cyclization conditions to give *cis*-fused cyclopenta-pyridazinone **28** in 85% yield (Scheme 7). Similarly the pyridazinone **epi-27** was treated under these radical cyclization conditions and yielded cyclopenta-pyridazinone **epi-28**. Assignment of the relative and absolute configuration of our compounds was verified by X-ray analysis of compound **epi-28** (Scheme 8).

Finally, we have examined application of this methodology to the aza-spirocyclic found in halichlorine. Initially we explored the potential of cleaving the N-N bond in **29** using dissolving metal conditions with sodium in place of lithium. Use of sodium in ammonia provided the bicyclic lactam **30** in a 72% yield (Scheme 9). It should be recognized that the cyclopenta-lactams **22** and **30** could also serve as potential intermediates for accessing halichlorine.¹⁵

Acylation of **29** with TFAA followed by treatment with SmI₂ afforded the ring opened product **31** (Scheme 9). The TBS group was removed and alcohol **32** was treated under Mitsunobu conditions. Unfortunately, all attempts to cause the S_N2 displacement of the C₅ alcohol and its derivatives to give the aza-spirocyclic **33** were futile; elimination products were formed predominately.

In summary, the pyridazinone ring system has served as an excellent scaffold for preparing novel *cis*-fused cyclopenta-pyridazinones utilizing the directed 5-*exo* radical cyclization approach discussed above. This strategy to access compounds like **7**, **8**, **21** and **28** presents a direct, diastereoselective method to access these substructures that contain a new quaternary stereocenter in essentially enantiomerically pure form.

In the context of an approach to halichlorine, the rigid pyridazinone ring system led to the facile and highly diastereoselective installation of the *cis*-C₉-C₁₃ cyclopentane ring as well as the C₁₄ methyl found in halichlorine. The CAA reaction provided a highly stereoselective method to generate the remote hydroxy stereocenter that was slated to provide the C₅-N bond of the aza-spirocyclic. However, the ring closure from this intermediate will require further study.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgement

Financial assistance provided by the NIH (through grant GM29861) is gratefully acknowledged.

References

- (1). (a) Jasperse CP, Curran DP, Fevig TL. *Chem. Rev* 1991;91:1237. (b) Marco-Contelles J, Ruiz P, Sanchez B, Jimeno ML. *Tetrahedron Lett* 1992;33:5261. (c) Curran DP, Sisko J, Yeske PE, Liu H. *Pure Appl. Chem* 1993;65:1153. (d) Keck GE, Wager TT, McHardy SF. *J. Org. Chem* 1998;63:9164.

- (2). (a) Ueno Y, Chino K, Watanabe M, Moriya O, Okawara M. *J. Am. Chem. Soc* 1982;104:5564. (b) Stork G, Mook R, Biller SA, Rychnovsky SD. *J. Am. Chem. Soc* 1983;105:3741. (c) Choi J-K, Hart DJ. *Tetrahedron* 1985;41:3959. (d) Fukuzawa, S.-i; Tsuchimoto, T. *Synlett* 1993:803. (e) Miyata O, Nishiguchi A, Ninomiya I, Aoe K, Okamura K, Naito T. *J. Org. Chem* 2000;65:6922. [PubMed: 11031011]
- (3). For examples of hydrazone acceptors, see:(a)Sturino CF, Fallis AG. *J. Am. Chem. Soc* 1994;116:7447.(b)Marco-Contelles J, Balme G, Bouyssi D, Destabel C, Henriet-Bernard CD, Grimaldi J, Hatem JM. *J. Org. Chem* 1997;62:1202.(c)Tauh P, Fallis AG. *J. Org. Chem* 1999;64:6960.(d)Friestad GK, Fioroni GM. *Org. Lett* 2005;7:2393. [PubMed: 15932206]For examples of imine acceptors, see:(e)Tomaszewski MJ, Warkentin J. *Chem. Commun* 1993:966.(f)Bowman WR, Stephenson PT, Terrett NK, Young AR. *Tetrahedron Lett* 1994;35:6369.(g)Kim S, Yoon KS, Kim YS. *Tetrahedron* 1997;53:73.For examples of *N*-aziridinylimine acceptors, see:(h)Kim S, Kee IS, Lee S. *J. Am. Chem. Soc* 1991;113:9882.(i)Lee H-Y, Kim D-I, Kim S. *Chem. Commun* 1996:1539.For examples of oxime acceptors, see:(j)Keck GE, Wager TT. *J. Org. Chem* 1996;61:8366.(k)Miyata O, Muroya K, Koide J, Naito T. *Synlett* 1998:271.(l)Keck GE, Wager TT, Rodriguez JFD. *J. Am. Chem. Soc* 1999;121:5176.(m)Clive DLJ, Pham MP, Subedi R. *J. Am. Chem. Soc* 2007;129:2713. [PubMed: 17284033]
- (4). (a) Parker KA, Spero DM, Van Epp J. *J. Org. Chem* 1988;53:4628. (b) Takano S, Suzuki M, Kijima A, Ogasawara K. *Chem. Lett* 1990:315. (c) Booth SE, Jenkins PR, Swain CJ, Sweeney JB. *J. Chem. Soc., Perkin Trans. 1* 1994:3499. (d) Clive DLJ, Zhang J, Subedi R, Bouetard V, Hiebert S, Ewanuk R. *J. Org. Chem* 2001;66:1233. [PubMed: 11312953]
- (5). (a) Myers AG, Yang BG, Chen H, Gleason JL. *J. Am. Chem. Soc* 1994;116:9361. (b) Myers AG, Yang BH, Chen H, McKinsty L, Kopecky DJ, Gleason JL. *J. Am. Chem. Soc* 1997;119:6496.
- (6). During our initial studies, the enantiomer of the compounds shown in schemes 2, 3, 5, and 6 was used. For simplicity, only one enantiomer is consistently shown throughout all schemes.
- (7). (a) El Hashash MA, El Kady MY, Mohamed MM. *Ind. J. Chem. Sect. B: Org. Chem. Incl. Med. Chem* 1979;18B:136. (b) Best WM, Brown RFC, Tiso PD, Watson KG. *Aust. J. Chem* 1990;43:427. (c) Essawy SA. *Ind. J. Chem. Sect. B: Org. Chem. Incl. Med. Chem* 1991;30B:371.
- (8). (a) Cignarella G, Barlocco D, Pinna GA, Loriga M, Curzu MM, Tofanetti O, Germini M, Cazzulani P, Cavalletti E. *J. Med. Chem* 1989;32:2277. [PubMed: 2795599] (b) Combs DW, Rampulla MS, Demers JP, Falotico R, Moore JB. *J. Med. Chem* 1992;35:172. [PubMed: 1732525] (c) Stajer G, Szabo A, Bernath G, Sohar P. *Heterocycles* 1994;38:1061.
- (9). For total syntheses of halichlorine, see:(a)Trauner D, Schwarz JB, Danishefsky SJ. *Angew. Chem. Int. Ed* 1999;38:3542.(b)Christie HS, Heathcock CH. *Proc. Natl. Acad. Sci. U.S.A* 2004;101:12079. [PubMed: 15299146]For a comprehensive review of synthetic approaches, see:(c)Clive DLJ, Yu M, Wang J, Yeh VSC, Kang S. *Chem. Rev* 2005;105:4483. [PubMed: 16351051]For recent synthetic approaches not covered in ref 9c, see:(d)Andrade RB, Martin SF. *Org. Lett* 2005;7:5733. [PubMed: 16321034](e)Kim H, Seo JH, Shin KJ, Kim DJ, Kim D. *Heterocycles* 2006;70:143.(f)Sinclair A, Arini LG, Rejzek M, Szeto P, Stockman RA. *Synlett* 2006;14:2321.(g)Hurley PB, Dake GR. *J. Org. Chem* 2008;73:4231.
- (10). Kuramoto M, Tong C, Yamada K, Chiba T, Hayashi Y, Uemura D. *Tetrahedron Lett* 1996;37:3867.
- (11). (a) Bevilacqua MP, Nelson RM, Mannori G, Cecconi O. *Annu. Rev. Med* 1994;45:361. [PubMed: 7515220] (b) Carlos TM, Harlan JM. *Blood* 1994;84:2068. [PubMed: 7522621] (c) Foster CA. *J. Allergy Clin. Immunol* 1996;98:S270. [PubMed: 8977536] (d) Yusuf-Makagiansar H, Anderson ME, Yakovleva TV, Murray JS, Siahaan TJ. *Med. Res. Rev* 2002;22:146. [PubMed: 11857637]
- (12). The more obvious sequence of alkylation after radical cyclization was found to give much lower levels of diastereoselectivity for introduction of the methyl group (*ca* 2:1)
- (13). (a) Ding H, Friestad GK. *Org. Lett* 2004;6:637. [PubMed: 14961642] (b) Friestad GK, Marie J-C, Deveau AM. *Org. Lett* 2004;6:3249. [PubMed: 15355024]
- (14). (a) Keck GE, Tarbet KH, Geraci LS. *J. Am. Chem. Soc* 1993;115:8467. (b) Keck GE, Krishnamurthy D. *Org. Syn* 1998;75:12.
- (15). See intermediate **6** in reference 9a.

Scheme 1.
Formation of Cyclopenta-pyridazinone

Scheme 2.
Synthesis of Functionalized Pyridazinones

Scheme 3.
5-Exo Radical Cyclization

Scheme 4.
Retrosynthetic Analysis of Halichlorine 9

Scheme 5.
Installation of C₁₄ Methyl and C₉-C₁₃ Cyclopentane

Scheme 6.
Formation of Aza-spirocycle via Mitsunobu

Scheme 7.
CAA and 5-exo Radical Cyclization

Scheme 8.
Synthesis and ORTEP Representation of **epi-28**

Scheme 9.
Approach to Halichlorine's Aza-spirocycle